Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INDV
Strong BuyFull HouseFLAGIndivior Pharmaceuticals, Inc. · Healthcare · United States · $4.1B · Avg Vol: $81M/d
Indivior has value at V41, below the calibrated floor, so the strong M84 momentum and plus 4.4% revision cannot carry it, and insiders sold 0.06%. Opioid addiction treatment with a complex litigation and competitive history.
COMPANY DESCRIPTION
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company focused on developing and commercializing treatments for opioid use disorder (OUD) and other serious mental health conditions. The company possesses a leading market position in the treatment of opioid dependence, particularly with its flagship product Sublocade, benefiting from intellectual property protection and established clinical efficacy. It is a dedicated pharmaceutical company addressing the opioid crisis with innovative long-acting injectable treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 901.0M | 1.1B | 1.2B | 1.2B | 11.2% | 1.3B | 1.3B | 1.4B | 6.3% |
| EPS | -0.38 | 0.01 | -0.36 | 1.68 | 1196.1% | 2.79 | 2.96 | 3.10 | 35.7% |
| Shares | 136.5M | 136.5M | 124.9M | 125.0M | -8.4% | 118.0M | — | — | — |
| Debt | 277.0M | 283.0M | 375.0M | 351.0M | 8.2% | 509.0M | — | — | — |
| Equity | 51.0M | -192.0M | -337.0M | -99.0M | — | — | — | — | — |
| Op CF | -4.0M | -300.0M | 36.0M | -27.0M | — | -40.0M | — | — | — |
| Inv CF | -222.0M | -95.0M | 69.0M | -66.0M | — | — | — | — | — |
| Fin CF | -101.0M | -64.0M | -102.0M | -30.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INDV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INDV | Indivior Pharmaceuticals, Inc.(you) | $4.1B | 94 | Strong Buy |
| LNTH | Lantheus Holdings, Inc. | $6.6B | 88 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.1B | 83 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 94 | Strong Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 92 | Strong Buy |
| AMPH | Amphastar Pharmaceuticals, Inc. | $936M | 95 | Strong Buy |
| NBIX | Neurocrine Biosciences, Inc. | $15.7B | 85 | Strong Buy |
| PCRX | Pacira BioSciences, Inc. | $1.0B | 85 | Strong Buy |
Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.1%